Irinotecan Eugia

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Eugia, is a topoisomerase I inhibitor presented as a sterile injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, primarily in adult patients requiring systemic chemotherapy, and is commonly used within combination regimens such as FOLFIRI under the supervision of qualified healthcare professionals.

GNH USA supplies Irinotecan Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and procurement teams worldwide, ensuring quality‑assured product availability and regulatory compliance.

Irinotecan Eugia is a topoisomerase I inhibitor used in colorectal cancer chemotherapy.

Colorectal cancer (adjuvant setting): improves disease‑free survival when added to postoperative chemotherapy. Metastatic colorectal cancer (first‑line): forms part of combination regimens to reduce tumor burden. Metastatic colorectal cancer (second‑line): provides an alternative after progression on oxaliplatin‑based therapy.

Irinotecan Eugia may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: often delayed and may be severe. - Neutropenia: reduced white blood cell count. - Nausea and vomiting. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils. - Life‑threatening diarrhea (colitis) leading to dehydration. - Cholinergic syndrome: sweating, bradycardia, bronchospasm. - Hypersensitivity reactions: rash, anaphylaxis.

When using Irinotecan Eugia, several precautions should be observed to minimize risks and ensure safe administration.

- Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: adjust dose in hepatic impairment. - Maintain hydration: adequate fluids reduce severity of diarrhea. - Avoid strong UGT1A1 inhibitors: drugs like atazanavir may increase toxicity. - Pregnancy and lactation: use only if potential benefit justifies risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Eugia can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong UGT1A1 inhibitors (e.g., atazanavir, indinavir): increase SN‑38 exposure. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma levels. - Concurrent myelosuppressive agents: heightened risk of severe neutropenia. - Anticholinergic drugs: may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, St. John’s wort): may reduce effectiveness. - Warfarin: monitor INR as irinotecan may affect coagulation. - NSAIDs: increase risk of gastrointestinal toxicity.